<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302379</url>
  </required_header>
  <id_info>
    <org_study_id>U54 CA155435-01 Project 3</org_study_id>
    <nct_id>NCT01302379</nct_id>
  </id_info>
  <brief_title>Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors</brief_title>
  <official_title>Obesity-related Mechanisms and Mortality in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle
      intervention and metformin (a drug used to treat diabetes) to investigate how these
      treatments, alone or in combination, affect biomarkers associated with breast cancer
      survival. The Reach for Health Study will enroll 340 overweight/obese, postmenopausal breast
      cancer survivors. After completing the screening process and baseline measures, participants
      will be randomized in equal numbers to: (1) placebo, (2) metformin, (3) lifestyle
      intervention and placebo, or (4) lifestyle intervention and metformin. The intervention was
      powered on the main effects and the planned analyses are to compare: Metformin to Placebo and
      a separate comparison of Lifestyle intervention to control. The interventions will last for 6
      months. Concentrations of circulating biomarkers will be assessed at baseline and 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Main effects of the factorial design were the planned primary analysis and what the study was powered on.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>Insulin measured as percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>Glucose measured as percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>C-reactive protein measured as percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailable Testosterone</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>Bioavailable testosterone measured as percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Hormone Binding Globulin</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>Serum hormone binding globulin measured as percent change from baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time</description>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time</description>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard printed dietary guidelines</intervention_name>
    <description>Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI at least 25.0 kg/m2

          -  Diagnosed with Stage I, II, or III breast cancer within past 5 years

          -  Treatment with total mastectomy or breast-sparing surgical removal of cancer with
             clear macroscopic margins, and axillary dissection, followed by adjuvant breast
             radiation

          -  Not scheduled for or currently undergoing chemotherapy

          -  Accessible geographically and by telephone

          -  Able to communicate dietary and physical activity data via telephone

          -  If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on
             treatment for 6-month study period

          -  Post-menopausal at diagnosis

        Exclusion Criteria:

          -  Preliminary bloodwork outside of specified ranges

          -  Evidence of renal insufficiency, liver disease, or congestive heart failure

          -  Currently taking corticosteroid pills or steroid hormone therapy (including vaginal
             estrogen creams)

          -  Recent initiation (&lt; 3 months ago) of thiazides or Î²-blockers

          -  Taking insulin or other antidiabetic drug

          -  Other primary or recurrent invasive cancer in past 10 years

          -  Unable to commit to study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>December 10, 2018</results_first_submitted>
  <results_first_submitted_qc>May 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Ruth E. Patterson</investigator_full_name>
    <investigator_title>Professor, Department of Family &amp; Preventive Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Survival</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Metformin</keyword>
  <keyword>Biological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin + Lifestyle Intervention</title>
          <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Lifestyle Intervention</title>
          <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
        </group>
        <group group_id="P3">
          <title>Metformin + Standard Dietary Guidelines</title>
          <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Standard Dietary Guidelines</title>
          <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin + Lifestyle Intervention</title>
          <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Lifestyle Intervention</title>
          <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
        </group>
        <group group_id="B3">
          <title>Metformin + Standard Dietary Guidelines</title>
          <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Standard Dietary Guidelines</title>
          <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="83"/>
            <count group_id="B5" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="7.1"/>
                    <measurement group_id="B2" value="62.9" spread="62.1"/>
                    <measurement group_id="B3" value="62.1" spread="6.3"/>
                    <measurement group_id="B4" value="63.1" spread="7.4"/>
                    <measurement group_id="B5" value="62.6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race or Other race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.9"/>
                    <measurement group_id="B2" value="3.1" spread="2.4"/>
                    <measurement group_id="B3" value="2.6" spread="1.9"/>
                    <measurement group_id="B4" value="2.5" spread="1.7"/>
                    <measurement group_id="B5" value="2.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="5.2"/>
                    <measurement group_id="B2" value="30.8" spread="4.6"/>
                    <measurement group_id="B3" value="30.8" spread="4.7"/>
                    <measurement group_id="B4" value="31.5" spread="5.4"/>
                    <measurement group_id="B5" value="31.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin</title>
        <description>Insulin measured as percent change from baseline</description>
        <time_frame>change from baseline to 6 months</time_frame>
        <population>Obese or overweight postmenopausal breast cancer survivors</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Lifestyle Intervention</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Intervention</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Standard Dietary Guidelines</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Standard Dietary Guidelines</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin</title>
          <description>Insulin measured as percent change from baseline</description>
          <population>Obese or overweight postmenopausal breast cancer survivors</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" lower_limit="-29.7" upper_limit="-13.0"/>
                    <measurement group_id="O2" value="-17.7" lower_limit="-25.9" upper_limit="-8.6"/>
                    <measurement group_id="O3" value="-13.2" lower_limit="-21.7" upper_limit="-3.7"/>
                    <measurement group_id="O4" value="-1.1" lower_limit="-10.9" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose</title>
        <description>Glucose measured as percent change from baseline</description>
        <time_frame>change from baseline to 6 months</time_frame>
        <population>Obese or overweight postmenopausal breast cancer survivors</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Lifestyle Intervention</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Intervention</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Standard Dietary Guidelines</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Standard Dietary Guidelines</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>Glucose measured as percent change from baseline</description>
          <population>Obese or overweight postmenopausal breast cancer survivors</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-3.9" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-4.9" upper_limit="0.4"/>
                    <measurement group_id="O3" value="-1.6" lower_limit="-4.2" upper_limit="1.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="-0.7" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein</title>
        <description>C-reactive protein measured as percent change from baseline</description>
        <time_frame>change from baseline to 6 months</time_frame>
        <population>Obese or overweight postmenopausal breast cancer survivors</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Lifestyle Intervention</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Intervention</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Standard Dietary Guidelines</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Standard Dietary Guidelines</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein</title>
          <description>C-reactive protein measured as percent change from baseline</description>
          <population>Obese or overweight postmenopausal breast cancer survivors</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" lower_limit="-38.9" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-27.4" upper_limit="19.7"/>
                    <measurement group_id="O3" value="-9.2" lower_limit="-29.0" upper_limit="16.1"/>
                    <measurement group_id="O4" value="5.9" lower_limit="-17.4" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioavailable Testosterone</title>
        <description>Bioavailable testosterone measured as percent change from baseline</description>
        <time_frame>change from baseline to 6 months</time_frame>
        <population>Obese or overweight postmenopausal breast cancer survivors</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Lifestyle Intervention</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Intervention</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Standard Dietary Guidelines</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Standard Dietary Guidelines</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailable Testosterone</title>
          <description>Bioavailable testosterone measured as percent change from baseline</description>
          <population>Obese or overweight postmenopausal breast cancer survivors</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" lower_limit="-20.3" upper_limit="-6.5"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-11.7" upper_limit="3.4"/>
                    <measurement group_id="O3" value="-11.1" lower_limit="-17.8" upper_limit="-3.9"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-8.7" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Hormone Binding Globulin</title>
        <description>Serum hormone binding globulin measured as percent change from baseline</description>
        <time_frame>change from baseline to 6 months</time_frame>
        <population>Obese or overweight postmenopausal breast cancer survivors</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Lifestyle Intervention</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Intervention</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Standard Dietary Guidelines</title>
            <description>Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Standard Dietary Guidelines</title>
            <description>Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Standard printed dietary guidelines: Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hormone Binding Globulin</title>
          <description>Serum hormone binding globulin measured as percent change from baseline</description>
          <population>Obese or overweight postmenopausal breast cancer survivors</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.9" upper_limit="19.6"/>
                    <measurement group_id="O2" value="7.6" lower_limit="1.4" upper_limit="14.3"/>
                    <measurement group_id="O3" value="9.8" lower_limit="3.5" upper_limit="16.5"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-5.9" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-97.5</ci_lower_limit>
            <ci_upper_limit>97.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Across the 6 month intervention</time_frame>
      <desc>The study was designed and powered for a main effects analysis and therefore the results are presented as per the original statistical plan: Metformin vs. Placebo and Lifestyle intervention vs. Control.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin vs Placebo</title>
          <description>Main effect for Metformin vs Placebo</description>
        </group>
        <group group_id="E2">
          <title>Lifestyle vs. Control</title>
          <description>Main effect for the lifestyle intervention vs control intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injury due to fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
              <event>
                <sub_title>slurred speach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
              <event>
                <sub_title>transient neurological defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruth Patterson</name_or_title>
      <organization>University of San Diego, California</organization>
      <phone>8585349235</phone>
      <email>repatterson@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

